AIDS Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185-Blok A, B-9000 Ghent, Belgium.
J Antimicrob Chemother. 2014 Apr;69(4):1098-103. doi: 10.1093/jac/dkt484. Epub 2013 Dec 12.
To identify host and viral characteristics associated with long-term persisting low-level viraemia (PLLV) under antiretroviral therapy (ART).
Seventy-one ART-treated patients with long-term PLLV (20-250 copies/mL) and 102 control patients with systematically undetectable viral load (VL) were selected retrospectively from ART-treated patients followed at the Ghent HIV reference centre. Host and viral characteristics were compared using univariate and multivariate analyses.
Higher plasma VL at therapy initiation (OR 3.52; 95% CI 1.86-6.65; P < 0.001), therapy re-initiation after an interruption (OR 3.94; 95% CI 1.70-9.16; P = 0.001), male gender (OR 4.28; 95% CI 1.40-13.00; P = 0.011), a protease inhibitor-based regimen (OR 2.90; 95% CI 1.20-6.97; P = 0.017) and predicted CCR5 co-receptor tropism (OR 2.53; 95% CI 1.05-6.11; P = 0.039) were independently associated with PLLV.
VL at ART initiation, therapy history, gender, ART regimen and co-receptor tropism were independently associated with PLLV. Gender, therapy history, co-receptor tropism and VL at ART initiation could be valuable predictive markers to identify patients at risk for PLLV.
确定与抗逆转录病毒治疗（ART）下长期持续低水平病毒血症（PLLV）相关的宿主和病毒特征。
从在根特 HIV 参考中心接受治疗的患者中回顾性选择了 71 名接受 ART 治疗且长期 PLLV（20-250 拷贝/mL）的患者和 102 名系统检测不到病毒载量（VL）的对照患者。使用单变量和多变量分析比较了宿主和病毒特征。
治疗开始时的血浆 VL 较高（OR 3.52；95%CI 1.86-6.65；P < 0.001）、中断后重新开始治疗（OR 3.94；95%CI 1.70-9.16；P = 0.001）、男性（OR 4.28；95%CI 1.40-13.00；P = 0.011）、基于蛋白酶抑制剂的方案（OR 2.90；95%CI 1.20-6.97；P = 0.017）和预测的 CCR5 共受体嗜性（OR 2.53；95%CI 1.05-6.11；P = 0.039）与 PLLV 独立相关。
ART 开始时的 VL、治疗史、性别、ART 方案和共受体嗜性与 PLLV 独立相关。性别、治疗史、共受体嗜性和 ART 开始时的 VL 可能是识别 PLLV 风险患者的有价值的预测标志物。
